For informational purposes only. Not financial advice, not a recommendation to buy or sell any security. Standing Order is a directory and research project, not an advisory service.
Price · 1Y
$14.97
Thesis
Schrödinger combines physics-based molecular simulation with machine learning, monetizing through software licenses and a proprietary drug pipeline. The dual model pairs recurring software revenue with optionality on internal and partnered programs.
Catalysts
- Software revenue growth and customer expansion
- Proprietary pipeline clinical progress
- Collaboration milestones with large pharma
Recent events
Material filings, federal awards, and regulatory activity. Impact is scored against market cap.
- Jun 29OtherSEC
Schrödinger files 8-K disclosing item 7.01 (Regulation FD).
- Jun 23LeadershipSEC
8-K reports Item 5.02 officer/director changes and Item 5.07 shareholder vote results.
- Jun 8LeadershipSEC
8-K filing (items 5.02, 9.01) disclosing officer or director changes.
- May 20LeadershipSEC
8-K filing (items 5.02, 7.01) disclosing officer or director changes.
- May 5Financial resultsSEC
Filed 8-K (items 2.02, 9.01) disclosing financial results.